Trial Profile

A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 13 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ADCT 701 (Primary)
Indications Adrenocortical carcinoma; Liver cancer; Neuroendocrine carcinoma; Solid tumours
Focus Adverse reactions; First in man

Most Recent Events

25 Jan 2025 Trial design presented at the 2025 Gastrointestinal Cancers Symposium
29 Jul 2024 According to Chiome Bioscience media release, the first patient was dosed in this trial
19 Jun 2024 Planned initiation date changed from 23 Jun 2024 to 17 Jun 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com